E, Chiara Susini M, Guglielmelli P, Pieri L, Maggi L, Caini S, Palli D, Bogani C, Ponziani V, Pancrazzi A, Annunziato F, Bosi A: Enhanced risk of lymphoid neoplasms in patients with Philadelphia chromosome-negative myeloproliferative neoplasms. Cancer Epidemiol Biomarkers Prev 2009, 18:2068?073. four. Woronzoff-Dashkoff KK, Litz CE: Acute lymphoblastic leukemia inside a case of vital thrombocythemia. Am J Clin Pathol 1996, 106:206?08. five. Jurisic V, Colovic N, Terzic T, Djordjevic V, Colovic M: Transformation of principal myelofibrosis with 20q- in Philadelphia-positive acute lymphoblastic leukemia: case report and critique of literature. Pathol Res Pract 2012, 208:420?23. 6. Levine RL: JAK-mutant myeloproliferative neoplasms. Curr Top Microbiol Immunol 2012, 355:119?33. 7. Bercovich D, Ganmore I, Scott LM, Wainreb G, Birger Y, Elimelech A, Shochat C, Cazzaniga G, Biondi A, Basso G, Cario G, Schrappe M, Stanulla M, Strehl S, Haas OA, Mann G, Binder V, Borkhardt A, Kempski H, Trka J, Bielorei B, Avigad S, Stark B, Smith O, Dastugue N, Bourquin JP, Tal NB, Green AR, Izraeli S: Mutations of JAK2 in acute lymphoblastic leukaemias associated with Down’s syndrome. Lancet 2008, 372:1484?492. 8. Corbin AS, Agarwal A, Loriaux M, Cortes J, Deininger MW, Druker BJ: Human chronic myeloid leukemia stem cells are insensitive to imatinib regardless of inhibition of BCR-ABL activity. J Clin Invest 2011, 121:396?09. 9. Mahon FX, Rea D, Guilhot J, Guilhot F, Huguet F, Nicolini F, Legros L, Charbonnier A, Guerci A, Varet B, Etienne G, Reiffers J, Rousselot P: Discontinuation of imatinib in individuals with chronic myeloid leukaemia that have maintained full molecular remission for at the least 2 years: the potential, multicentre Cease Imatinib (STIM) trial. Lancet Oncol 2010, 11:1029?035.4-Propionylbenzoic acid web ten.2538602-07-0 manufacturer Hotfilder M, Rottgers S, Rosemann A, Schrauder A, Schrappe M, Pieters R, Jurgens H, Harbott J, Vormoor J: Leukemic stem cells in childhood high-risk ALL/t(9;22) and t(four;11) are present in primitive lymphoid-restricted CD34 + CD19- cells. Cancer Res 2005, 65:1442?449.PMID:24120168 11. Castor A, Nilsson L, Astrand-Grundstrom I, Buitenhuis M, Ramirez C, Anderson K, Strombeck B, Garwicz S, Bekassy AN, Schmiegelow K, Lausen B, Hokland P, Lehmann S, Juliusson G, Johansson B, Jacobsen SE: Distinct patterns of hematopoietic stem cell involvement in acute lymphoblastic leukemia. Nat Med 2005, 11:630?37. 12. le Viseur C, Hotfilder M, Bomken S, Wilson K, Rottgers S, Schrauder A, Rosemann A, Irving J, Stam RW, Shultz LD, Harbott J, Jurgens H, Schrappe M, Pieters R, Vormoor J: In childhood acute lymphoblastic leukemia, blasts at diverse stages of immunophenotypic maturation have stem cell properties. Cancer Cell 2008, 14:47?8. 13. Kong Y, Yoshida S, Saito Y, Doi T, Nagatoshi Y, Fukata M, Saito N, Yang SM, Iwamoto C, Okamura J, Liu KY, Huang XJ, Lu DP, Shultz LD, Harada M, Ishikawa F: CD34 + CD38 + CD19+ at the same time as CD34 + CD38-CD19+ cells are leukemia-initiating cells with self-renewal capacity in human B-precursor ALL. Leukemia 2008, 22:1207?213. 14. Steensma DP, Dewald GW, Lasho TL, Powell HL, McClure RF, Levine RL, Gilliland DG, Tefferi A: The JAK2 V617F activating tyrosine kinase mutation is definitely an infrequent occasion in each “atypical” myeloproliferative disorders and myelodysplastic syndromes. Blood 2005, 106:1207?209. 15. Schepers K, Pietras EM, Reynaud D, Flach J, Binnewies M, Garg T, Wagers AJ, Hsiao EC, Passegue E: Myeloproliferative neoplasia remodels the endosteal bone marrow niche into a self-reinforc.
